Gilead Sciences Q2 EPS $1.34 Misses $1.61 Estimate, Sales $6.60B Beat $6.43B Estimate
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences reported Q2 earnings of $1.34 per share, missing the analyst consensus estimate of $1.61 by 16.77%. This is a 15.19% decrease from the same period last year. However, the company's quarterly sales of $6.60 billion beat the analyst consensus estimate of $6.43 billion by 2.63%, marking a 5.42% increase from last year.
August 04, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences' Q2 earnings per share missed estimates by 16.77%, but sales exceeded expectations by 2.63%.
Gilead Sciences' Q2 earnings per share fell short of analyst estimates, which could negatively impact investor sentiment and potentially lead to a short-term decrease in the company's stock price. However, the company's sales exceeded expectations, which could offset some of the negative impact.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100